Patent Expiry

Patent/Exclusivity Expiry: VENCLEXTA

September 6, 2033

Company: Actinium Pharmaceuticals, Inc. (ATNM)
Drug: VENCLEXTA

Other upcoming events for ATNM

Phase 1 StartPhase 1 Start: A Phase I Trial of 225Ac-anti-CD33 and PD1-Inhibitor in Recurrent Glioblastoma

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Patent/Exclusivity Expiry: VENCLEXTA — ATNM Patent Expiry | BioSniper